Who owns CIRION BIOPHARMA RESEARCH?

CIRION BIOPHARMA RESEARCH has been 100% owned by CERBA HEALTHCARE since September 2023.

What was the revenue of CIRION BIOPHARMA RESEARCH at the time of the deal?

The revenue of CIRION BIOPHARMA RESEARCH at the time of the deal is estimated to be in the range of 5M - 25M EUR.

How is the data for the CIRION BIOPHARMA RESEARCH acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CIRION BIOPHARMA RESEARCH deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/build-up/cerba-healthcare-simplante-au-canada-1977900

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaCIRION BIOPHARMA RESEARCH

09/2023

CIRION BIOPHARMA RESEARCH acquired by CERBA HEALTHCARE

CANADA Healthcare Services / CRO / Clinical Trials REV 5M - 25M EUR

Context

Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs. The transaction followed Cerba's previous major international acquisitions of Lifebrain (Italy) and Viroclinics-DDL (Netherlands), furthering the global expansion strategy initiated under EQT's majority ownership since 2021.

By taking control of Cirion Biopharma Research, Cerba Healthcare continues its expansion strategy. Previously, the group had completed 3 acquisitions, including Labexa in 2021.

CIRION BIOPHARMA RESEARCH, which reported an EBITDA margin of in 2022, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Cirion is a premier Canadian Contract Research Organization (CRO) specializing in bioanalytical laboratory services for the pharmaceutical and biotechnology industries. The company provides integrated support across the entire drug development lifecycle, from preclinical research to Phase III clinical trials. Key areas of expertise include Pharmacokinetics/Pharmacodynamics (PKPD) assay development, immunogenicity testing, and large molecule analysis. Cirion operates a state-of-the-art facility in Laval that is fully compliant with GLP (Good Laboratory Practice) and North American regulatory standards (FDA/Health Canada), serving a global client base that includes several of the world's top 10 pharmaceutical companies. The team consists of over 80 highly skilled professionals, including PhD holders and medical specialists.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Healthcare Services

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services
10/2023	MOTION EQUITY PARTNERS	BANOOK	FRANCE	CRO / Clinical Trials
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	CRO / Clinical Trials
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Health Tech
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services
11/2020	KERSIA	SOPURA	BELGIUM	Sterilization & Hygiene
10/2020	IK PARTNERS	KERSIA	FRANCE	Sterilization & Hygiene
05/2020	CLAYTON, DUBILIER & RICE (CD&R)	HUNTSWORTH	UNITED KINGDOM	Healthcare Services
03/2020	LDC	AGENTIS HEALTH GROUP	UNITED KINGDOM	Healthcare Services
01/2018	SPECTRIS	CONCEPT LIFE SCIENCES	UNITED KINGDOM	CRO / Clinical Trials

REFERENCES

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CIRION BIOPHARMA RESEARCH by CERBA HEALTHCARE are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: cerba healthcare